MDGLvs its industry peers
A metric-by-metric comparison of MDGL against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGLEsta | $9.3B#5 | — | 14.8x#10 | 9.7x#1 | 432.1%#1 | 38.1%#3 | -31.3%#1 | -46.0%#12 | -66.2%#4 | — | — | — |
| MRNA | $103.0B#1 | — | 15.1x#11 | 53.0x#4 | -39.9%#7 | 20.8%#6 | -158.1%#4 | -41.3%#11 | -49.3%#3 | — | — | — |
| TWST | $7.6B#8 | — | 17.0x#12 | 20.1x#2 | 20.3%#5 | 62.8%#1 | -36.2%#2 | -17.4%#7 | -41.4%#2 | — | 294.1%#2 | — |
| ORKA | $6.8B#10 | — | 6.1x#5 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | — | — |
| KYMR | $11.2B#3 | — | 7.0x#7 | 286.7x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 19.3%#1 | — | — | — | — |
| VKTX | $3.4B#14 | — | 5.8x#4 | — | — | -227.1%#15 | — | -61.1%#14 | — | — | -28.0%#4 | — |
| PRAX | $7.8B#7 | — | 5.8x#3 | — | -100.0%#9 | -65.6%#11 | — | -22.6%#9 | — | — | — | — |
| ERAS | $5.0B#12 | — | 13.9x#9 | — | — | 23.0%#5 | — | -34.4%#10 | — | — | — | — |
| RVMD | $41.6B#2 | — | 17.3x#13 | — | — | -88.5%#13 | — | -47.1%#13 | — | — | — | — |
| RYTM | $7.8B#6 | — | 88.5x#14 | 41.0x#3 | 45.8%#4 | 24.6%#4 | -101.2%#3 | -0.2%#3 | -127.5%#5 | — | — | — |
| CGON | $6.8B#11 | — | 6.8x#6 | 1678.9x#7 | 254.7%#3 | -82.9%#12 | -4722.1%#7 | -16.2%#6 | -19.8%#1 | — | — | — |
| SLS | $1.7B#15 | — | 12.3x#8 | — | -100.0%#9 | 13.0%#7 | — | -19.5%#8 | — | — | 421.1%#1 | — |
| PCVX | $10.1B#4 | — | 4.1x#2 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | 53.1%#3 | — |
| DNTH | $4.8B#13 | — | 3.9x#1 | 2377.1x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.1%#5 | — | — | — | — |
| CYTK | $7.5B#9 | — | — | 85.0x#5 | 376.6%#2 | -33.2%#9 | -695.4%#5 | — | — | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-08.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice